Nektar Therapeutics (NASDAQ:NKTR) Director Robert Chess sold 6,400 shares of the firm’s stock in a transaction dated Thursday, September 21st. The stock was sold at an average price of $21.72, for a total value of $139,008.00. Following the transaction, the director now directly owns 274,223 shares in the company, valued at approximately $5,956,123.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Nektar Therapeutics (NKTR) opened at 23.10 on Thursday. The stock’s market cap is $3.61 billion. The company’s 50 day moving average price is $20.15 and its 200-day moving average price is $19.77. Nektar Therapeutics has a 12-month low of $11.41 and a 12-month high of $24.88.

Nektar Therapeutics (NASDAQ:NKTR) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.04). The company had revenue of $34.60 million during the quarter, compared to analyst estimates of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.36) EPS. On average, analysts forecast that Nektar Therapeutics will post ($0.94) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/28/nektar-therapeutics-nktr-director-sells-139008-00-in-stock.html.

Several equities analysts have issued reports on NKTR shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Nektar Therapeutics in a report on Friday, July 21st. Zacks Investment Research raised Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a report on Tuesday, August 1st. ValuEngine raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. William Blair reaffirmed an “outperform” rating on shares of Nektar Therapeutics in a report on Monday, June 26th. Finally, BidaskClub lowered Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company. Nektar Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $26.45.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NKTR. BlackRock Inc. raised its stake in Nektar Therapeutics by 180,432.9% during the first quarter. BlackRock Inc. now owns 20,035,546 shares of the biopharmaceutical company’s stock worth $470,234,000 after acquiring an additional 20,024,448 shares during the period. Janus Henderson Group PLC acquired a new stake in Nektar Therapeutics during the second quarter worth about $34,661,000. PointState Capital LP raised its stake in Nektar Therapeutics by 281.7% during the second quarter. PointState Capital LP now owns 1,731,000 shares of the biopharmaceutical company’s stock worth $33,841,000 after acquiring an additional 1,277,500 shares during the period. MARSHALL WACE ASIA Ltd acquired a new stake in Nektar Therapeutics during the first quarter worth about $23,580,000. Finally, Marshall Wace North America L.P. acquired a new stake in Nektar Therapeutics during the first quarter worth about $23,580,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.